Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Investing Activities (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of Cash from Investing Activities data on record, last reported at -$2.1 million in Q2 2025.

  • For Q2 2025, Cash from Investing Activities rose 22.71% year-over-year to -$2.1 million; the TTM value through May 2025 reached -$6.4 million, up 65.13%, while the annual FY2025 figure was -$6.4 million, 65.13% up from the prior year.
  • Cash from Investing Activities reached -$2.1 million in Q2 2025 per LFCR's latest filing, down from $1.5 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $65.2 million in Q1 2022 and bottomed at -$17.5 million in Q2 2022.
  • Average Cash from Investing Activities over 5 years is $1.8 million, with a median of -$3.6 million recorded in 2022.
  • Peak YoY movement for Cash from Investing Activities: soared 16159.05% in 2021, then crashed 2136.28% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$5.4 million in 2021, then rose by 29.06% to -$3.8 million in 2022, then dropped by 10.73% to -$4.3 million in 2023, then soared by 42.74% to -$2.4 million in 2024, then rose by 14.06% to -$2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$2.1 million in Q2 2025, $1.5 million in Q1 2025, and -$2.4 million in Q4 2024.